Compare Amphastar Pharmaceuticals Inc (AMPH) vs Brunswick Corporation (BC) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

BC trades at $77.9, down 0.12% on the day, with a bearish technical signal but strong analyst support. The stock shows mixed fundamentals with a high P/E of 73.92 and negative net income margin of -2.47%, though revenue remains stable near $5.4 billion. Recent news highlights operational updates and expansion milestones, including Freedom Boat Club's 450th location opening (GlobeNewsWire, June 23, 2026).

Outlook is cautiously optimistic given the 71% buy rating from analysts and an $86.40 consensus price target, but risks include persistent negative profitability and high debt levels. The upcoming Q2 2026 earnings report on July 30, 2026 (GlobeNewsWire, July 9, 2026) will be critical for confirming turnaround potential.